Sustained Reversal Of Established Pulmonary Fibrosis With Pegylated Interferon Alpha Treatment For Hepatitis C Virus Infection

2010 ◽  
Author(s):  
Sophie V. Fletcher ◽  
Yvonne Buggy ◽  
Stephen Harden ◽  
Katherine M.A. O'Reilly
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Pulmonary Fibrosis ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Hepatitis C Virus Infection ◽  
Pegylated Interferon Alpha ◽  
Interferon Alpha Treatment

scholarly journals Existing and future therapeutic options for hepatitis C virus infection.

2005 ◽  
Vol 52 (1) ◽  
pp. 57-70 ◽  
Author(s):  
Maria Bretner
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Pegylated Interferon ◽  
Host Immune System ◽  
Hepatitis C Virus Infection ◽  
Pegylated Interferon Alpha ◽  
Ifn Alpha ◽  
Viral Receptors

Hepatitis C virus (HCV) infection is an important cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma and liver failure worldwide. Chronic hepatitis C virus infection is treated with interferon-a (IFN-alpha), pegylated interferon-alpha (PEG-IFNalpha) alone or in combination with ribavirin; however, a significant fraction of patients either fail to respond or relapse after cessation of therapy. Efforts to identify and develop highly specific and potent HCV inhibitors have intensified recently. Each of the virally encoded replication enzymes has been a focus of studies as well as viral receptors and the host immune system. This review summarizes recent progress in the search for novel anti-HCV agents.

Sign in / Sign up

Export Citation Format

Share Document